Quantitative and Qualitative Analysis of Humoral Immunity Reveals Continued and Personalized Evolution in Chronic Viral Infection
Author(s) -
Nike Julia Kräutler,
Alexander Yermanos,
Alessandro Pedrioli,
Suzanne P. M. Welten,
Dominique Lorgé,
Ute Greczmiel,
Ilka Bartsch,
Jörg Scheuermann,
Jonathan D. Kiefer,
Klaus Eyer,
Ulrike Menzel,
Victor Greiff,
Dario Neri,
Tanja Stadler,
Sai T. Reddy,
Annette Oxenius
Publication year - 2020
Publication title -
cell reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.264
H-Index - 154
eISSN - 2639-1856
pISSN - 2211-1247
DOI - 10.1016/j.celrep.2019.12.088
Subject(s) - lymphocytic choriomeningitis , germinal center , biology , antibody , chronic infection , antibody repertoire , immunology , virology , repertoire , immune system , virus , immunity , humoral immunity , acquired immune system , b cell , cd8 , physics , acoustics
Control of established chronic lymphocytic choriomeningitis virus (LCMV) infection requires the production of neutralizing antibodies, but it remains unknown how the ensemble of antibodies evolves during ongoing infection. Here, we analyze the evolution of antibody responses during acute or chronic LCMV infection, combining quantitative functional assays and time-resolved antibody repertoire sequencing. We establish that antibody responses initially converge in both infection types on a functional and repertoire level, but diverge later during chronic infection, showing increased clonal diversity, the appearance of mouse-specific persistent clones, and distinct phylogenetic signatures. Chronic infection is characterized by a longer-lasting germinal center reaction and a continuous differentiation of plasma cells, resulting in the emergence of higher-affinity plasma cells exhibiting increased antibody secretion rates. Taken together, our findings reveal the emergence of a personalized antibody response in chronic infection and support the concept that maintaining B cell diversity throughout chronic LCMV infection correlates with the development of infection-resolving antibodies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom